Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 15/20 | 0.43 |
| ▸ | ESR1 | P03372 | 10/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PON1 | P27169 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5730945 | 0.91 | ESR1 (0.46) | NQO1ESR2ESR1CSNK2A2CSNK2B | |
| SCHEMBL5120320 | 0.84 | ESR2 (0.43) | NQO1ESR2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5117787 | 0.77 | ESR2 (0.40) | NQO1ESR2ESR1CSNK2A2CSNK2B | |
| SCHEMBL5118711 | 0.77 | CSNK2A2 (0.47) | ESR2ESR1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5115327 | 0.76 | FAAH (0.37) | ESR2 | |
| SCHEMBL5126114 | 0.76 | MAPT (0.38) | NQO1ESR2ESR1 | |
| SCHEMBL5115329 | 0.76 | MAOB (0.44) | NQO1ESR2ESR1CSNK2A2CSNK2B | |
| SCHEMBL5111278 | 0.75 | ALDH1A1 (0.48) | MAOB | |
| SCHEMBL5118825 | 0.75 | NQO1 (0.52) | NQO1ESR2ESR1CSNK2A2CSNK2B | |
| SCHEMBL5125176 | 0.73 | MAOB (0.56) | NQO1CSNK2A2CSNK2BCSNK2A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384975-B2 | Substituted furochromenes, preparation thereof and their antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-06-10 | — | — | US | claimed |
| US-20060148889-A1 | Substituted furochromenes, preparation thereof and their antiinflammatory action | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | claimed |
| US-7384975-B2 | Substituted furochromenes, preparation thereof and their antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-06-10 | — | — | US | disclosed |
| US-7384975-B2 | Substituted furochromenes, preparation thereof and their antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-06-10 | — | — | US | disclosed |
| US-7384975-B2 | Substituted furochromenes, preparation thereof and their antiinflammatory action | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-06-10 | — | — | US | disclosed |
| US-20060148889-A1 | Substituted furochromenes, preparation thereof and their antiinflammatory action | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148889-A1 | Substituted furochromenes, preparation thereof and their antiinflammatory action | CYP11B2, CYP11B1, LTC4S | NQO1 60/4885ESR2 962/4885ESR1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.